Friday, Oct 21st

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.


Most Recent Related Stories...

Americans overwhelmingly support abortion rights

Americans support abortion rightsPolitical candidates, consultants and the media generally misunderstand the politics of abortion rights. They tend to...

France to open first safe-injection room for drug addicts

safe heroin injection room opened in FranceFrance will open its first safe-injection room for drug addicts despite years of efforts by conservatives...

St. Jude warns of heart-device battery issue linked to two deaths

St. Jude'sSt. Jude Medical Inc warned on Tuesday that some of its implanted heart devices were at...

EpiPen maker Mylan to pay $465M to settle claims it overbilled Medicaid

Mylan to pay for Medicaid fraudEmbattled pharmaceutical company Mylan agreed Friday to pay nearly a half-billion dollars to settle claims that...
America's # 1 Enemy
Tee Shirt
& Help Support!
TVNL Tee Shirt
Conserve our Planet
& Help Support!
Get your 9/11 & Media
Deception Dollars
& Help Support!
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!